US biotech company Biogen (BIIB) expects lower profits in 2025, affected by stronger dollar (DX = F, DX-Y.NYB) and competes for its multiple sclerosis (MS) drugs.
Still, the company beat fourth-quarter expectations, driven by cost cuts and new product launches, including its Alzheimer’s drug.
Watch the video above to hear hosts Brad Smith and Seana Smith discuss the latest developments in Biogen.
To see more expert insights and analysis on the latest market actions, see more morning summary here.
This article was written by Josh Lynch
